%0 Generic
%A Capdevila, J.
%A Landolfi, S.
%A Hernando, J.
%A Teule, A.
%A Garcia-Carbonero, R.
%A Custodio, A.
%A Cubillo, A.
%A Alonso-Gordoa, T.
%A Carmona-Bayonas, A.
%A Crespo, G.
%A Blanco, M.
%A Viudez, A.
%A La Casta, A.
%A Sevilla, I.
%A Segura, A.
%A Lopez, C.
%A Benavent Vinuales, M.
%A Nuciforo, P.
%A Manzano, J. L.
%T Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601)
%D 2021
%@ 0923-7534
%U https://hdl.handle.net/10668/27028
%X Background.Previously reported treatment efficacy with durvalumab (D) plus tremelimumab (T) showed limited activity in patients (pts) with well differentiated neuroendocrine tumors (NETs). However, primary endpoint was achieved in grade 3 (G3) neuroendocrine neoplasms (NENs) suggesting a promising overall survival rate in a pretreated population. Here we update the results of the G3 cohort with central pathological review.Methods.DUNE was a prospective open-label trial that recruited pts with advanced NENs after progression to standard therapies in four cohorts (C1-4): typical/atypical lung carcinoids (C1), G1/2 gastrointestinal (C2), G1/2 pancreatic (C3), and G3 NENs of gastroenteropancreatic origin after progression to first-line platinum-based chemotherapy (C4). Pts received 1500 mg durvalumab (D) (up to 13 cycles) plus 75 mg tremelimumab (T)(up to 4 cycles) once every 4 weeks. Primary objective for C4 was the 9 months (m) overall survival rate (OS) expected to be over 23%.
%K Humans
%K Neuroendocrine Tumors
%K Survival Rate
%K Carcinoid Tumor
%K Gastrointestinal Neoplasms
%K Treatment Outcome
%K Lung
%~